On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

KaloBios Pharmaceuticals, Inc. (KBIO) is “One to Watch”

With more people across the U.S. faced with the unpleasant fact that healthcare and pharmaceutical costs are exceptionally high and continuing to grow, KaloBios Pharmaceuticals, Inc. (OTC: KBIO) is taking a step closer to positive change with new, innovative, and responsible pricing models.

The company is leading a new way of thinking regarding how medicines are priced, and how to tackle neglected and rare diseases. KBIO is advancing treatments and medicines for patients through innovative and responsible business models, leading by example with concrete operational changes, such as its Responsible Pricing Model.

This model was recently recognized in an article entitled ‘Will Investors Reward Drugmakers That Limit Price Increases?’ by Medical Marketing & Media (http://nnw.fm/HW0pb). The article highlights the problems that healthcare systems are facing, with the Epipen as an example, voicing a common professional medical investor fear that “this parade of pricing scandals makes us look like a pack of scoundrels. Sure, the EpiPen is a marvel. But that doesn’t mean it should be unaffordable! For a small number of patients, Daraprim can be life-saving. But that shouldn’t mean you should hike its price overnight by 50-fold!”

The article continues with an explanation of KaloBios’ new incentive to confine its revenue expectations to a “reasonable return.” With this in mind, KaloBios believes that, to achieve real transformation in the way the healthcare system operates as well as among patients and stakeholders, transparency and collaboration are key.

KaloBios Pharmaceuticals, Inc. is in the business of developing therapeutics for the treatment of cancer in the United States. The company’s Responsible Pricing Program means it is affordable to patients while maintaining a reasonable and transparent profit margin. KBIO does not make arbitrary price increases on its products, and keeps a close eye on inflation and the Consumer Price Index (CPI).

For more information, visit the company’s website at www.KaloBios.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217